KR101470352B1 - 위장관 및 면역-관련 질환의 예방 및 치료를 위한 바실루스ｐｂ6의 용도 - Google Patents

위장관 및 면역-관련 질환의 예방 및 치료를 위한 바실루스ｐｂ6의 용도 Download PDF

Info

Publication number
KR101470352B1
KR101470352B1 KR1020087015832A KR20087015832A KR101470352B1 KR 101470352 B1 KR101470352 B1 KR 101470352B1 KR 1020087015832 A KR1020087015832 A KR 1020087015832A KR 20087015832 A KR20087015832 A KR 20087015832A KR 101470352 B1 KR101470352 B1 KR 101470352B1
Authority
KR
South Korea
Prior art keywords
bacillus
treatment
diarrhea
delete
difficile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020087015832A
Other languages
English (en)
Korean (ko)
Other versions
KR20080073771A (ko
Inventor
벤네딕트 사스
요한 반 헤멜
얀 반덴커트호베
에릭 페이스
헤이 멩 탄
체-윤 세
챠니일파람푸 람챈드
제리 바르게세
Original Assignee
케민 인더스트리즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케민 인더스트리즈, 인코포레이티드 filed Critical 케민 인더스트리즈, 인코포레이티드
Publication of KR20080073771A publication Critical patent/KR20080073771A/ko
Application granted granted Critical
Publication of KR101470352B1 publication Critical patent/KR101470352B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020087015832A 2005-11-29 2008-06-27 위장관 및 면역-관련 질환의 예방 및 치료를 위한 바실루스ｐｂ6의 용도 Expired - Fee Related KR101470352B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74051805P 2005-11-29 2005-11-29
US60/740,518 2005-11-29
PCT/US2006/045755 WO2007064741A2 (en) 2005-11-29 2006-11-29 The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases

Publications (2)

Publication Number Publication Date
KR20080073771A KR20080073771A (ko) 2008-08-11
KR101470352B1 true KR101470352B1 (ko) 2014-12-09

Family

ID=38092773

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087015832A Expired - Fee Related KR101470352B1 (ko) 2005-11-29 2008-06-27 위장관 및 면역-관련 질환의 예방 및 치료를 위한 바실루스ｐｂ6의 용도

Country Status (13)

Country Link
US (1) US20080057047A1 (enExample)
EP (1) EP1956914B1 (enExample)
JP (2) JP5280854B2 (enExample)
KR (1) KR101470352B1 (enExample)
CN (1) CN101448398B (enExample)
AU (1) AU2006320613B2 (enExample)
BR (1) BRPI0619364A2 (enExample)
CA (1) CA2631289C (enExample)
IL (1) IL191795A (enExample)
NZ (1) NZ569244A (enExample)
RU (1) RU2412241C2 (enExample)
WO (1) WO2007064741A2 (enExample)
ZA (1) ZA200804646B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230057289A (ko) * 2021-10-20 2023-04-28 주식회사 리빙진 바실러스 밸레젠시스 Kh2-2 균주를 포함하는 면역증강용 조성물

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ587549A (en) 2004-06-24 2012-10-26 Vertex Pharma 6-Amino-indole derivatives and processes for their preparation
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US20100092428A1 (en) * 2008-09-17 2010-04-15 Joseph Earl Schmidt Method For Using A Bacillus Subtilis Strain To Enhance Animal Health
US11028454B2 (en) * 2008-09-24 2021-06-08 Resilux Incorporation of thermo-resistant and/or pressure-resistant organisms in materials
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
WO2011111783A1 (ja) * 2010-03-12 2011-09-15 カルピス株式会社 大腸におけるビフィズス菌の増加及び減少抑制剤
WO2011116155A1 (en) 2010-03-17 2011-09-22 Agraquest, Inc. Method for using a bacillus subtilis strain for prophylaxis and treatment of gastro-intestinal conditions
EP2593187A4 (en) 2010-07-16 2014-04-09 Univ Arkansas PROCESSES AND COMPOSITIONS WITH SPORTS-BUILDING BACTERIA TO IMPROVE THE HEALTH OF ANIMALS
WO2012044984A1 (en) 2010-09-30 2012-04-05 The Board Of Trustees Of The University Of Arkansas Methods of selecting and using therapeutic and prophylactic probiotic cultures to reduce bacterial pathogen loads
US20140127215A1 (en) * 2010-12-29 2014-05-08 Cangene Corporation Clostridium difficile antigens
AU2013226076B2 (en) 2012-02-27 2017-11-16 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
WO2014022572A1 (en) 2012-08-01 2014-02-06 Pacific Vet Group-Usa, Inc. Probiotic for amelioration of coccidiosis vaccine reaction
RU2534356C2 (ru) * 2012-10-04 2014-11-27 Государственное научное учреждение Институт экспериментальной ветеринарии Сибири и Дальнего Востока Россельхозакадемии (ГНУ ИЭВСиДВ Россельхозакадемии) Способ контроля качества дезинфекции птицеводческих помещений
FR2999191B1 (fr) * 2012-12-12 2016-02-05 Lesaffre & Cie Souches probiotiques pour le traitement et/ou la prevention de la diarrhee
FR3007655B1 (fr) * 2013-06-28 2016-12-23 Lesaffre & Cie Souche bacillus subtilis pour le traitement et/ou la prevention de maladies inflammatoires chroniques
EP2923710A1 (en) 2014-03-27 2015-09-30 Universitätsklinikum Heidelberg Bacterial phospholipase inhibitors as modulator of colonic bacterial flora
US20170224745A1 (en) * 2014-07-25 2017-08-10 The University Of Queensland Bacillus amyloliquefaciens probiotic compositions, methods of production, and methods of use
CA3000621C (en) 2014-09-30 2024-02-27 Auburn University Use of pectin or pectin-related saccharides to enhance efficacy of plant growth-promoting rhizobacteria (pgpr) strains for promoting growth and health in plants and animals
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
JP6595761B2 (ja) * 2014-12-19 2019-10-23 東亜薬品工業株式会社 バチルスアミロリキファシエンス菌株及び該菌株を含む抗菌組成物
BR112017015623B1 (pt) 2015-01-23 2022-05-31 Novozymes A/S Ração animal ou aditivo de ração animal ou pré-mistura de ração, método para melhora de um ou mais parâmetros de desempenho de um animal e para alimentação de um animal, e, uso de uma cepa de bacillus
FI3247788T3 (fi) 2015-01-23 2023-08-18 Novozymes As Bacillus-kannat, jotka parantavat tuotantoeläinten terveyttä ja suorituskykyä
PL3261653T3 (pl) 2015-01-23 2020-03-31 Novozymes A/S Podgatunek bacillus subtilis
CA2987013C (en) * 2015-05-30 2022-05-31 Japan Eco-Science Co., Ltd. Probiotic or prebiotic, method for producing same, microbial preparation, health food, and medicine
US10857190B2 (en) 2015-10-06 2020-12-08 Albert Einstein College Of Medicine Microbial hyperswarmers and uses thereof
US11571012B2 (en) * 2015-10-26 2023-02-07 CJ Wellcare Corporation Strain derived from traditional fermented food and having excellent enzyme productivity, and method for preparing fermented cereal enzyme food by using same
RU2641979C1 (ru) * 2016-10-24 2018-01-23 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московская государственная академия ветеринарной медицины и биотехнологии - МВА имени К.И. Скрябина" (ФГБОУ ВО МГАВМиБ - МВА имени К.И. Скрябина) Способ морфологической оценки влияния различных лекарственных форм железа для энтерального применения на тонкий отдел кишечника у экспериментальных животных
US20200113952A1 (en) * 2017-06-30 2020-04-16 Evonik Operations Gmbh Bacillus subtilis strain with probiotic activity
US20190289878A1 (en) * 2018-03-23 2019-09-26 Purina Animal Nutrition Llc Methods of feeding animals feed products containing direct-fed microbials
BR112020024798B1 (pt) * 2018-06-07 2023-05-02 Artugen Therapeutics Ltd Composição compreendendo cepas bacterianas
CA3127549A1 (en) * 2019-05-14 2020-11-19 Ormendes Sa Use of bacillus amyloliquefaciens and/or bacillus subtilis for the enhancement of active probiotic compositions or for the activation of inactive probiotic compositions, compositions thus obtained, and related method
WO2020257769A1 (en) * 2019-06-21 2020-12-24 The Board Of Trustees Of The University Of Arkansas Bacillus isolate compositions and methods of using and producing the same
GB201911925D0 (en) 2019-08-20 2019-10-02 Sporegen Ltd Formulations for prevention or reduction of c. difficile infections
WO2021116983A1 (en) * 2019-12-11 2021-06-17 Artugen Therapeutics, Ltd. Edible products comprising bacterial strains and methods of use
KR20220154154A (ko) * 2020-03-13 2022-11-21 케민 인더스트리즈, 인코포레이티드 동물의 클로스트리디움 감염 제어 방법
GB202013874D0 (en) * 2020-09-03 2020-10-21 Sporegen Ltd Treatment and prevention of viral infections
EP4258875A4 (en) 2020-12-09 2024-11-20 Purina Animal Nutrition LLC Feed compositions and methods for inhibiting focal ulcerative dermatitis
CN113151069B (zh) * 2021-04-01 2022-07-26 安杰利(重庆)生物科技有限公司 一种枯草芽孢杆菌及其在制备抗菌肽、饲料中的应用
WO2023220279A1 (en) * 2022-05-12 2023-11-16 Can Technologies, Inc. Compositions and methods for the treatment and prevention of campylobacter infection
CN115725461B (zh) * 2022-11-03 2024-03-19 东北农业大学 一株具有抗幽门螺杆菌作用的解淀粉芽孢杆菌及其应用
FR3158224A1 (fr) * 2024-01-12 2025-07-18 Lesaffre Et Compagnie Effet bénéfique d’une bactérie probiotique Bacillus subtilis dans la lutte contre les infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050832A2 (en) * 2002-11-27 2004-06-17 Kemin Industries, Inc. Antimicrobial compounds from bacillus subtilis for use against animal and human pathogens
WO2005059112A1 (en) * 2003-12-17 2005-06-30 Kt & G Co., Ltd The novel bacillus amyloliquefaciens ktgb0202 and control method of plant pathogenic funzi using that
JP2005198518A (ja) * 2004-01-13 2005-07-28 Asahi Business Support Co Ltd 海苔屑分解処理法及び微生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4968493A (en) * 1986-06-30 1990-11-06 American Cyanamid Company Method for controlling chronic respiratory disease, fowl cholera and necrotic enteritis in avian species
US5352586A (en) * 1987-05-01 1994-10-04 Biogaia Ab Method of determining the presence of an antibiotic produced by Lactobacillus reuteri
ZA926834B (en) * 1991-09-09 1993-03-15 American Cyanamid Co Antibiotic LL-E19020 Gamma.
TW455591B (en) * 1993-06-08 2001-09-21 Hoechst Ag Lipopeptides from actinoplanes sp. with pharmacological action, process for their production and the use thereof
DE4411025A1 (de) * 1994-03-30 1995-10-05 Hoechst Ag Lipopeptid-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
JP2879321B2 (ja) * 1996-03-14 1999-04-05 久保田 豊秋 動物用経口組成物
PT862863E (pt) * 1997-01-09 2002-04-29 Nestle Sa Produto cerealifero contendo probioticos
US6461607B1 (en) * 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
FI110668B (fi) * 2000-06-20 2003-03-14 Aboatech Ab Oy Probioottien käyttö atooppisten sairauksien primaariseen ehkäisyyn
RU2246537C2 (ru) * 2002-11-11 2005-02-20 Закрытое акционерное общество "КУЛ" Штамм бактерий bacillus subtilis, используемый для получения пробиотического препарата, предназначенного для профилактики и лечения желудочно-кишечных заболеваний сельскохозяйственных животных, птицы и рыбы
JP4189224B2 (ja) * 2003-01-14 2008-12-03 株式会社カンサイ バチルス属に属する微生物及びそれを用いる防除剤
RU2270858C2 (ru) * 2004-03-30 2006-02-27 Институт биологии Уфимского научного центра РАН Штамм бактерий b. subtilis - продуцент сурфактина
US7854927B2 (en) * 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050832A2 (en) * 2002-11-27 2004-06-17 Kemin Industries, Inc. Antimicrobial compounds from bacillus subtilis for use against animal and human pathogens
WO2005059112A1 (en) * 2003-12-17 2005-06-30 Kt & G Co., Ltd The novel bacillus amyloliquefaciens ktgb0202 and control method of plant pathogenic funzi using that
JP2005198518A (ja) * 2004-01-13 2005-07-28 Asahi Business Support Co Ltd 海苔屑分解処理法及び微生物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230057289A (ko) * 2021-10-20 2023-04-28 주식회사 리빙진 바실러스 밸레젠시스 Kh2-2 균주를 포함하는 면역증강용 조성물
KR102546973B1 (ko) 2021-10-20 2023-06-26 주식회사 리빙진 바실러스 밸레젠시스 Kh2-2 균주를 포함하는 면역증강용 조성물

Also Published As

Publication number Publication date
WO2007064741A3 (en) 2008-05-08
JP5280854B2 (ja) 2013-09-04
US20080057047A1 (en) 2008-03-06
KR20080073771A (ko) 2008-08-11
RU2008121602A (ru) 2009-12-10
JP2009519238A (ja) 2009-05-14
BRPI0619364A2 (pt) 2011-09-27
CN101448398A (zh) 2009-06-03
WO2007064741A2 (en) 2007-06-07
JP2013173750A (ja) 2013-09-05
CN101448398B (zh) 2013-05-08
NZ569244A (en) 2012-07-27
RU2412241C2 (ru) 2011-02-20
CA2631289C (en) 2015-01-06
WO2007064741A8 (en) 2008-01-31
IL191795A0 (en) 2009-02-11
AU2006320613B2 (en) 2012-08-16
AU2006320613A1 (en) 2007-06-07
ZA200804646B (en) 2011-11-30
EP1956914A2 (en) 2008-08-20
EP1956914B1 (en) 2014-01-08
IL191795A (en) 2013-07-31
CA2631289A1 (en) 2007-06-07
EP1956914A4 (en) 2011-12-21

Similar Documents

Publication Publication Date Title
KR101470352B1 (ko) 위장관 및 면역-관련 질환의 예방 및 치료를 위한 바실루스ｐｂ6의 용도
US11896628B2 (en) Methods and compositions for the treatment of C. difficile
EP2179028B1 (en) A novel strain of bifidobacterium and active peptides against rotavirus infections
KR20200143944A (ko) 글루텐 분해능을 가지는 락토바실러스 파라카제이 glu70 균주의 사균체를 유효성분으로 함유하는 글리아딘으로 야기된 염증성 장 질환의 예방, 개선 또는 치료용 조성물
US20250170188A1 (en) Bacillus clausii strain, compositions thereof, and methods of use
KR102701916B1 (ko) 큐티박테리움 아비덤 균주, 그의 유래의 배양액 및 그의 항균 용도
KR20200099311A (ko) 글루텐 분해능을 가지는 락토바실러스 파라카제이 glu70 균주를 유효성분으로 함유하는 글리아딘으로 야기된 염증성 장 질환의 예방, 개선 또는 치료용 조성물
HK40100510A (en) B. amyloliquefaciens strain and therapeutic use
HK40098932A (en) B. amyloliquefaciens strain and therapeutic use
MX2008006778A (en) The use of bacillus pb6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
HK40047668B (en) B. amyloliquefaciens strain and therapeutic use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20171203

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20171203

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000